Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-3 fatty acids or sertraline for prevention of depression and cognitive decline in older adults
ACTRN12610000032055Phase 4Completed
- Sponsor
- University of Sydney
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in major depressive disorder (MDD) and No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity comparing Omega-3 fatty acids arm, Sertraline arm and Placebo arm (3 arms). Primary endpoint: Mean change in severity of depression symptoms at 12 months. Started Jun 2011; status: completed.
02
Drugs
sertralineomega-3 fatty acid
03
Conditions
major depressive disorder (MDD)No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on ACTRN12610000032055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000032055.